Encapsulated GDNF-producing C2C12 cells for Parkinson's disease: a pre-clinical study in chronic MPTP-treated baboons

[1]  P. Aebischer,et al.  Gene therapy approaches for Parkinson's disease , 2003 .

[2]  S. Konitsiotis,et al.  Complications of a trophic xenotransplant approach in parkinsonian monkeys , 2003, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[3]  D. Brooks,et al.  Direct brain infusion of glial cell line–derived neurotrophic factor in Parkinson disease , 2003, Nature Medicine.

[4]  Richard Grondin,et al.  Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys. , 2002, Brain : a journal of neurology.

[5]  I. Date,et al.  Neuroprotective and restorative effects of intrastriatal grafting of encapsulated GDNF‐producing cells in a rat model of Parkinson's disease , 2002, Journal of neuroscience research.

[6]  R. Bakay,et al.  Lentivirally Delivered Glial Cell Line-Derived Neurotrophic Factor Increases the Number of Striatal Dopaminergic Neurons in Primate Models of Nigrostriatal Degeneration , 2002, The Journal of Neuroscience.

[7]  Alexandre Mendes,et al.  Treatment results: Parkinson's disease , 2002, Movement disorders : official journal of the Movement Disorder Society.

[8]  H. Mizukami,et al.  Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson's disease , 2002, Gene Therapy.

[9]  A. Björklund,et al.  Neuroprotection in the rat Parkinson model by intrastriatal GDNF gene transfer using a lentiviral vector , 2002, Neuroreport.

[10]  L Lopiano,et al.  Deep brain stimulation of the subthalamic nucleus: anatomical, neurophysiological, and outcome correlations with the effects of stimulation , 2002, Journal of neurology, neurosurgery, and psychiatry.

[11]  P. Aebischer,et al.  Sustained delivery of GDNF: towards a treatment for Parkinson’s disease , 2001, Brain Research Reviews.

[12]  J Q Trojanowski,et al.  Transplantation of embryonic dopamine neurons for severe Parkinson's disease. , 2001, The New England journal of medicine.

[13]  J. Bloch,et al.  Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. , 2000, Science.

[14]  P Aebischer,et al.  Neuroprotective gene therapy for Huntington's disease using a polymer encapsulated BHK cell line engineered to secrete human CNTF. , 2000, Human gene therapy.

[15]  G. Donnan,et al.  New dopaminergic neurons in Parkinson's disease striatum , 2000, The Lancet.

[16]  P. Aebischer,et al.  Evaluation of an Intrathecal Immune Response in Amyotrophic Lateral Sclerosis Patients Implanted with Encapsulated Genetically Engineered Xenogeneic Cells , 2000, Cell transplantation.

[17]  J. Bloch,et al.  Restoration of cognitive and motor functions by ciliary neurotrophic factor in a primate model of Huntington's disease. , 2000, Human gene therapy.

[18]  Krishna Kumar,et al.  Deep Brain Stimulation of the Ventral Intermediate Nucleus of the Thalamus for Control of Tremors in Parkinson’s Disease and Essential Tremor , 2000, Stereotactic and Functional Neurosurgery.

[19]  Timothy Sendera,et al.  Clinicopathological findings following intraventricular glial‐derived neurotrophic factor treatment in a patient with Parkinson's disease , 1999, Annals of neurology.

[20]  Karl J. Friston,et al.  Statistical parametric mapping with 18F-dopa PET shows bilaterally reduced striatal and nigral dopaminergic function in early Parkinson’s disease , 1999, Journal of neurology, neurosurgery, and psychiatry.

[21]  A. Lang,et al.  Double-blind evaluation of subthalamic nucleus deep brain stimulation in advanced Parkinson's disease , 1998, Neurology.

[22]  C. Crouzel,et al.  6‐[18F]Fluoro‐L‐DOPA by radiofluorodestannylation: a short and simple synthesis of a new labelling precursor , 1998 .

[23]  C. Spenger,et al.  Implants of Polymer-Encapsulated Genetically Modified Cells Releasing Glial Cell Line-Derived Neurotrophic Factor Improve Survival, Growth, and Function of Fetal Dopaminergic Grafts , 1998, Experimental Neurology.

[24]  A. Björklund,et al.  Studies on Neuroprotective and Regenerative Effects of GDNF in a Partial Lesion Model of Parkinson's Disease , 1997, Neurobiology of Disease.

[25]  N. Déglon,et al.  A gene therapy approach to regulated delivery of erythropoietin as a function of oxygen tension. , 1997, Human gene therapy.

[26]  R. Turner,et al.  Dopaminergic Neurons Intrinsic to the Primate Striatum , 1997, The Journal of Neuroscience.

[27]  N. Déglon,et al.  Central nervous system delivery of recombinant ciliary neurotrophic factor by polymer encapsulated differentiated C2C12 myoblasts. , 1996, Human gene therapy.

[28]  Gunnar Brix,et al.  Performance evaluation of the whole-body PET scanner ECAT EXACT HR/sup +/ , 1996, 1996 IEEE Nuclear Science Symposium. Conference Record.

[29]  O. Andreassen,et al.  Estimation of the number of somatostatin neurons in the striatum: An in situ hybridization study using the optical fractionator method , 1996, The Journal of comparative neurology.

[30]  Myriam Schluep,et al.  Intrathecal delivery of CNTF using encapsulated genetically modifiedxenogeneic cells in amyotrophic lateral sclerosis patients , 1996, Nature Medicine.

[31]  B. Hoffer,et al.  Functional recovery in parkinsonian monkeys treated with GDNF , 1996, Nature.

[32]  D. Pipeleers,et al.  Expression and Functional Activity of Glucagon, Glucagon-Like Peptide I, and Glucose-Dependent Insulinotropic Peptide Receptors in Rat Pancreatic Islet Cells , 1996, Diabetes.

[33]  Vincent Frouin,et al.  Clinical correlates of {18F}fluorodopa uptake in five grafted Parkinsonian patients , 1995, Annals of neurology.

[34]  L. Olson,et al.  Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo , 1995, Nature.

[35]  R. Vandlen,et al.  Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain , 1995, Nature.

[36]  D. Riche,et al.  Chronic MPTP treatment reproduces in baboons the differential vulnerability of mesencephalic dopaminergic neurons observed in parkinson's disease , 1994, Neuroscience.

[37]  Y. Samson,et al.  Bilateral motor improvement and alteration of L-dopa effect in two patients with Parkinson's disease following intrastriatal transplantation of foetal ventral mesencephalon. , 1994, Brain : a journal of neurology.

[38]  G. Brownell,et al.  Dopamine Terminal Loss and Onset of Motor Symptoms in MPTP-Treated Monkeys: A Positron Emission Tomography Study with 11C-CFT , 1994, Experimental Neurology.

[39]  J. Lile,et al.  GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. , 1993, Science.

[40]  D. Riche,et al.  Stable parkinsonian syndrome and uneven loss of striatal dopamine fibres following chronic MPTP administration in baboons , 1993, Neuroscience.

[41]  N Satyamurthy,et al.  Regioselective radiofluorodestannylation with [18F]F2 and [18F]CH3COOF: a high yield synthesis of 6-[18F]Fluoro-L-dopa. , 1992, International journal of radiation applications and instrumentation. Part A, Applied radiation and isotopes.

[42]  H. Gundersen,et al.  Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator , 1991, The Anatomical record.

[43]  C D Marsden,et al.  Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease. , 1990, Science.

[44]  Richard F. Martin,et al.  Primate neostriatal neurons containing tyrosine hydroxylase: Immunohistochemical evidence , 1987, Neuroscience Letters.

[45]  C. Patlak,et al.  Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data. Generalizations , 1985, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[46]  S. Hsu,et al.  Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. , 1981, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[47]  Banknieder Ar,et al.  Comparison of ketmine with the combination of ketamine and xylazine for effective anesthesia in the rhesus monkey (Macaca mulatta). , 1978 .

[48]  P. Aebischer,et al.  Encapsulated neural transplants. , 2000, Progress in brain research.

[49]  Karl J. Friston,et al.  Spatial registration and normalization of images , 1995 .

[50]  Karl J. Friston,et al.  Statistical parametric maps in functional imaging: A general linear approach , 1994 .

[51]  Karl J. Friston,et al.  Comparing Functional (PET) Images: The Assessment of Significant Change , 1991, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.